Sunny Pharmtech (6676) Stock Overview
Engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
6676 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Sunny Pharmtech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$15.60 |
| 52 Week High | NT$20.10 |
| 52 Week Low | NT$12.90 |
| Beta | 0.085 |
| 1 Month Change | -1.89% |
| 3 Month Change | 13.87% |
| 1 Year Change | -21.80% |
| 3 Year Change | -30.97% |
| 5 Year Change | n/a |
| Change since IPO | -33.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6676 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.6% | -6.8% | -0.4% |
| 1Y | -21.8% | -4.2% | 49.8% |
Return vs Industry: 6676 underperformed the TW Pharmaceuticals industry which returned -4.2% over the past year.
Return vs Market: 6676 underperformed the TW Market which returned 49.8% over the past year.
Price Volatility
| 6676 volatility | |
|---|---|
| 6676 Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in TW Market | 10.1% |
| 10% least volatile stocks in TW Market | 2.4% |
Stable Share Price: 6676's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6676's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 158 | Yon-Lian Wu | www.sunnypharmtech.com |
Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; aminocaproic acid tablets for blood diseases, as well as for hyper-proteolytic enzymes; and carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage, as well as Cyclophosphamide injection for malignant diseases. The company was founded in 2014 and is based in Taoyuan City, Taiwan.
Sunny Pharmtech Inc. Fundamentals Summary
| 6676 fundamental statistics | |
|---|---|
| Market cap | NT$2.33b |
| Earnings (TTM) | -NT$269.51m |
| Revenue (TTM) | NT$290.18m |
Is 6676 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6676 income statement (TTM) | |
|---|---|
| Revenue | NT$290.18m |
| Cost of Revenue | NT$134.70m |
| Gross Profit | NT$155.48m |
| Other Expenses | NT$424.99m |
| Earnings | -NT$269.51m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 53.58% |
| Net Profit Margin | -92.88% |
| Debt/Equity Ratio | 43.7% |
How did 6676 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/17 16:13 |
| End of Day Share Price | 2026/03/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sunny Pharmtech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.